Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 ( <scp>DPP</scp> ‐4) inhibitor omarigliptin or the once‐daily <scp>DPP</scp> ‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy

Abstract

In patients with T2DM and inadequate glycaemic control on metformin, the addition of omarigliptin 25 mg once weekly or sitagliptin 100 mg once daily led to similar improvements in glycaemic control. Both agents were generally well tolerated with a low incidence of hypoglycaemia.